IRIS
CAVAZZONI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.269
EU - Europa 4.112
AS - Asia 2.132
AF - Africa 66
SA - Sud America 19
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 10.604
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.225
CN - Cina 1.218
IT - Italia 829
IE - Irlanda 795
FI - Finlandia 765
SE - Svezia 683
SG - Singapore 659
DE - Germania 340
UA - Ucraina 327
TR - Turchia 136
FR - Francia 85
GB - Regno Unito 77
IN - India 70
BE - Belgio 67
CI - Costa d'Avorio 65
AT - Austria 59
CA - Canada 44
NL - Olanda 28
CZ - Repubblica Ceca 18
IR - Iran 11
BR - Brasile 10
JP - Giappone 10
PL - Polonia 7
RU - Federazione Russa 7
HK - Hong Kong 6
VN - Vietnam 6
AR - Argentina 5
LT - Lituania 5
KR - Corea 4
LU - Lussemburgo 4
PK - Pakistan 4
CH - Svizzera 3
ES - Italia 3
EU - Europa 3
JO - Giordania 3
NZ - Nuova Zelanda 3
RO - Romania 3
AE - Emirati Arabi Uniti 2
EC - Ecuador 2
HU - Ungheria 2
ID - Indonesia 2
MK - Macedonia 2
PE - Perù 2
DK - Danimarca 1
EG - Egitto 1
HR - Croazia 1
SI - Slovenia 1
TW - Taiwan 1
Totale 10.604
Salva come PNG Salva come JPEG
Città #
Dublin 795
Chandler 760
Ann Arbor 509
Singapore 509
Jacksonville 378
Parma 286
Dearborn 281
Beijing 248
Boardman 220
Ashburn 209
Nanjing 178
Shanghai 163
Princeton 135
Izmir 132
San Mateo 113
New York 112
Bremen 87
Wilmington 84
Nanchang 71
Helsinki 69
Abidjan 65
Milan 57
Shenyang 57
Vienna 57
Kunming 56
Marseille 52
Des Moines 51
Brussels 50
Hebei 49
Hefei 49
Jinan 46
Los Angeles 41
Woodbridge 38
Tianjin 36
Toronto 31
Modena 30
Chicago 29
Jiaxing 29
Munich 27
Pune 27
Houston 26
Guangzhou 25
Seattle 25
Amsterdam 23
Changsha 23
Santa Clara 23
Redmond 22
Dallas 20
Wayne 20
Norwalk 19
Augusta 15
Fremont 15
Leawood 14
Frankfurt am Main 12
London 12
Zhengzhou 12
Fuzhou 11
Grafing 11
Neviano degli Arduini 11
Brno 10
Falls Church 10
Hangzhou 10
Monmouth Junction 10
Rome 10
Ardabil 9
Bologna 8
Chengdu 8
Ningbo 8
Redwood City 8
Reggio Emilia 8
Verona 8
Binche 7
Florence 7
Haikou 7
Lanzhou 7
Montreal 7
Rio Saliceto 7
Auburn 6
Auburn Hills 6
Borås 6
Dong Ket 6
Fairfield 6
Follonica 6
Leuven 6
Manchester 6
Mumbai 6
Pavia 6
Salsomaggiore Terme 6
Taiyuan 6
Taizhou 6
Xian 6
Düsseldorf 5
Fidenza 5
Genoa 5
Reggio Nell'emilia 5
Ardea 4
Bottanuco 4
Brescia 4
Buenos Aires 4
Busseto 4
Totale 6.828
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 208
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model 152
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 132
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 127
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 126
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 125
Characterization of gefitinib uptake in NSCLC cell lines 114
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 107
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 105
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 104
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 104
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 104
Intrapleural polymeric devices containing Cisplatin for malignant pleural Mesothelioma in a rat tumor model: a preliminary study. 103
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 100
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 98
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 98
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 98
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 97
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 95
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma 95
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 94
Intrapleural adjuvant treatment of mesothelioma : The combination of cisplatin-pemetrexed in rat tumor model 94
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 93
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 93
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 93
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 92
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 90
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 90
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 90
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 89
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 88
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 88
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 88
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 87
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 86
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 85
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 84
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 84
Cell culture studies of polysaccharide films loaded with cisplatin for the loco-regional therapy of malignant pleural mesothelioma 83
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 82
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 82
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 81
Roles of compatible osmolytes and heat shock protein 70 in the induction of tolerance to stresses in porcine endothelial cells 81
New treatment opportunities in phosphatase and tensin homolo(PTen)-deficient tumors: Focus on PTen/focal adhesion kinase pathway 80
5-benzylidene-hydantoins as new inhibitors of cell proliferation 80
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 80
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 79
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 79
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 78
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 78
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 78
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 77
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 76
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 76
Hypertonic stress and amino acid deprivation both increase expression of mRNA for amino acid transport system A 76
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 75
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 75
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 75
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 75
Induzione di osmotolleranza in cellule endoteliali derivate da arteria polmonare 74
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 74
Intrapleural application of polymeric films containing cisplatin and pemetrexed in a rat tumour model of malignant pleural mesothelioma 74
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 74
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 73
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 73
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 71
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 70
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 70
Irreversible EGFR inhibitor compounds with antiproliferative activity 70
Effect of constitutive expression of the fragile histidine triad gene on non small cell lung cancer 68
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 68
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 68
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 67
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 67
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 66
Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer 65
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 65
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 65
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 65
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 64
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 64
TRAIL-induced apoptosis of FHIT-negative lung cancer cells is inhibited by FHIT re-expression 64
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 64
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 64
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 62
Overcoming resistance of EGFR tyrosine kinase inhibitors by new cytostatic and proapoptotic drugs in non small cell lung cancer cell lines 62
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 62
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 62
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 62
The inducible coexpression of p53 and FHIT has a synergistic anti-proliferative effect in calu-1 lung cancer cell line 61
Antibacterial and antitumor activity of tetracyclic fluoroquinolones with pyrido[2,3-a]carbazole structure 61
Mannich base derivatives as novel EGFR irreversible inhibitors 61
Anti-proliferative effect of induced Fhit expression in non small cell lung cancer cell line (Calu-1) 61
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment 59
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 59
Effect of inducible FHIT and p53 expression on CALU-1 cell proliferation. 59
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 58
Optimizing EGFR inhibitor treatment in non small cell lung cancer 58
Biological hallmarks and new therapeutic approaches for the treatment of pdac 58
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 58
Totale 8.216
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.696
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.696
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.203 0 0 0 0 139 215 273 77 177 148 65 109
2020/20211.015 19 94 76 44 122 38 107 51 172 38 205 49
2021/2022727 49 30 34 48 13 13 100 67 44 59 38 232
2022/20233.057 284 318 212 211 276 345 27 252 968 17 114 33
2023/20241.287 66 98 49 56 105 299 95 86 44 67 125 197
2024/20251.177 133 212 273 314 245 0 0 0 0 0 0 0
Totale 10.845